



December 24, 2025

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA**

**Sub: Press Release on Zota Health Care raises Rs 350 crores through QIP issue**

With reference to the captioned subject; we, Zota Health Care Limited are forwarding herewith enclosed a copy of press release on Zota Health Care raising 350 crores through QIP issue.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**  
**Place: Surat**

Encl: Press Release

**Registered Office:**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601  
Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)  
Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)

CIN: L24231GJ2000PLC038352

## Zota Health Care raises Rs 350 crores through QIP issue

**Surat, December 24, 2025: Zota Health Care Ltd (NSE: Zota):** Zota Health Care Limited (“the Company”, “We”), a leading generics pharmacy retailer in India (Davaindia), has raised Rs 350 crores from a group of marquee investors through a Qualified Institutional Placement (QIP) issue.

The Company has allotted 22,80,130 equity shares to eligible Qualified Institutional Buyers (QIBs), including foreign portfolio investors, alternative investment funds, and mutual funds, at an issue price of Rs. 1,535 per equity share. Investors who participated in the issue include Valiant Partners, 360 ONE, Prashant Jain-led 3P Investment Managers, White Oak Capital, Sanshi Fund-I and Turnaround Opportunities Fund, among others.

**Commenting on successful fundraise, Mr. Ketankumar Zota, Chairman, Zota Health Care Limited said,** the continued support from institutional investors reflected confidence in the company’s long-term strategy and business model. *“We are grateful for the trust and support shown by our investors. It is particularly encouraging to see several existing investors participate in the QIP, reaffirming their belief in our vision and growth plans. The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the Company-Owned Company-Operated (COCO) stores of Davaindia nationwide, working capital requirements and general corporate purposes. The Company aims to open more than 5,000 Davaindia stores with the blend of COCO and Franchisee-Owned Franchisee-Operated (FOFO) stores across India by March 2029, supported by the fresh capital raised through QIP and cash flows from its mature store network.*

**As of now, we operate 2,253 Davaindia stores with the blend of 1,373 Company-Owned Company-Operated (COCO) stores and 880 Franchisee-Owned Franchisee-Operated (FOFO) stores.** *Zota Health Care has witnessed steady improvement in per-store revenues, driven by increasing consumer awareness and growing demand for affordable medicines. The company focuses on offering quality generic medicines at significantly lower prices compared to branded alternatives, making essential medicines more accessible to a wider population.”*

*Note: COCO stores are being operated by Davaindia Health Mart Limited, the Wholly Owned Subsidiary of the Company.*

### About Zota Health Care Limited:

Zota Health Care Ltd. (Zota), listed on the NSE, has been a key player in the Indian healthcare industry since 2000. Headquartered in Surat, Zota's team of over 520 professionals drives its growth and strong market presence. The company specialises in the development, manufacturing, and marketing of high-quality pharmaceutical, ayurvedic, nutraceutical, and over-the-counter products.

In 2017, Zota launched Davaindia, a generic pharmacy chain offering over 2,000 SKUs of quality medicines. For more information, visit: [www.zotahealthcare.com](http://www.zotahealthcare.com)

**For details please contact:**

**Mr. Ashvin Variya**

CS, Zota Health Care Ltd

E: [cszota@zotahealthcare.com](mailto:cszota@zotahealthcare.com)

**Mr. Siddesh Chawan**

Ernst & Young LLP, Investor Relations

E: [Siddesh.Chawan@in.ey.com](mailto:Siddesh.Chawan@in.ey.com)

**Mr. Ajit Mishra**

Ernst & Young LLP, Investor Relations

E: [Ajit.J.Mishra@in.ey.com](mailto:Ajit.J.Mishra@in.ey.com)

**Disclaimer:** Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Zota Health Care Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.